<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30258918</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">2352-3042</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>4</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2017</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Genes &amp; diseases</Title>                <ISOAbbreviation>Genes Dis</ISOAbbreviation>            </Journal>            <ArticleTitle>Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity.</ArticleTitle>            <Pagination>                <MedlinePgn>159-162</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gendis.2017.07.007</ELocationID>            <Abstract>                <AbstractText>The human epidermal growth factor receptor 2 (HER2) is overexpressed in 25%-30% of breast cancer patients. Anti-HER2 therapies have changed the aggressive course of HER2+ breast cancer. In spite of the therapeutic benefits, their cardiotoxicities are major concerns, especially when used concurrently with anthracyclines. Here we present an elderly patient with relapsed HER2+ breast cancer. Her presentation for relapsed disease was unusual for the physical finding as well as the history of trastuzumab-induced severe cardiotoxicity while requiring additional anti-HER2 therapy. She received neoadjuvant anti-HER2 treatment for stage III breast caner. Due to severe reduction of cardiac ejection fraction (EF), she only received five doses of adjuvant transtuzumab. Unfortunately her disease relapsed one year later with chest wall lesions and a persistent low EF. We treated the patient with lapatinib combined with capecitabine which resulted rapid resolution of her chest wall lesion. More importantly, the patient had one year of disease control without deterioration in her ejection fraction. We discussed the management of recurrent HER2+ breast cancer with chest wall disease and the choice of anti-HER2 therapy in patients with a history of transtuzumab-induced cardiac dysfunction.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sadek</LastName>                    <ForeName>Ibrahim</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Keaton</LastName>                    <ForeName>Mark</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maihle</LastName>                    <ForeName>Nita J</ForeName>                    <Initials>NJ</Initials>                    <AffiliationInfo>                        <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tang</LastName>                    <ForeName>Shou-Ching</ForeName>                    <Initials>SC</Initials>                    <AffiliationInfo>                        <Affiliation>Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300060, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2017</Year>                <Month>08</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>China</Country>            <MedlineTA>Genes Dis</MedlineTA>            <NlmUniqueID>101635967</NlmUniqueID>            <ISSNLinking>2352-3042</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2013;18(3):257-64</RefSource>                <PMID Version="1">23475636</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2012 Feb;13(2):135-44</RefSource>                <PMID Version="1">22257523</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2008 Dec 1;26(34):5544-52</RefSource>                <PMID Version="1">18955454</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Compr Canc Netw. 2012 Feb;10(2):286-8</RefSource>                <PMID Version="1">22308521</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1916-25</RefSource>                <PMID Version="1">26828775</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am Soc Clin Oncol Educ Book. 2016;35:e64-70</RefSource>                <PMID Version="1">27249772</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Apr 1;34(10):1034-42</RefSource>                <PMID Version="1">26598744</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomark Insights. 2015 Apr 08;10(Suppl 1):1-9</RefSource>                <PMID Version="1">25922571</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mol Cell Cardiol. 2006 Aug;41(2):228-35</RefSource>                <PMID Version="1">16769082</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>ESMO Open. 2016 Jul 21;1(4):e000073</RefSource>                <PMID Version="1">27843627</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 1992 Sep 3;327(10):685-91</RefSource>                <PMID Version="1">1463530</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Treat Rev. 2009 Nov;35(7):633-8</RefSource>                <PMID Version="1">19640652</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2015 Jan;26(1):113-9</RefSource>                <PMID Version="1">25355722</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2013 Feb;24(2):273-82</RefSource>                <PMID Version="1">22910839</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Mar 1;28(7):1124-30</RefSource>                <PMID Version="1">20124187</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2006 Dec 28;355(26):2733-43</RefSource>                <PMID Version="1">17192538</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):82-93</RefSource>                <PMID Version="1">17336464</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Dec 1;27(34):5838-47</RefSource>                <PMID Version="1">19884552</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Diagnosis and management</Keyword>            <Keyword MajorTopicYN="N">HER2 positive breast cancer</Keyword>            <Keyword MajorTopicYN="N">Lapatinib</Keyword>            <Keyword MajorTopicYN="N">Trastuzumab-induced cardiac toxicity</Keyword>            <Keyword MajorTopicYN="N">Unusual presentation</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>07</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2017</Year>                <Month>07</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30258918</ArticleId>            <ArticleId IdType="doi">10.1016/j.gendis.2017.07.007</ArticleId>            <ArticleId IdType="pii">S2352-3042(17)30046-6</ArticleId>            <ArticleId IdType="pmc">PMC6147109</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>